Alnylam Pharmaceuticals
(NASDAQ) ALNY
Alnylam Pharmaceuticals Financials at a Glance
Market Cap
$39.14B
Revenue (TTM)
$4.29B
Net Income (TTM)
$577.22M
EPS (TTM)
$4.21
P/E Ratio
69.66
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Price
$291.72
Volume
1,490,610.83
Open
$297.57
Price
$291.72
Volume
1,490,610.83
Open
$297.57
Previous Close
$291.37
Daily Range
$290.37 - $302.96
52-Week Range
$273.11 - $495.55
Estimated Earnings Date
Jul 30, 2026
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Price
$291.72
Volume
1,490,610.83
Open
$297.57
Previous Close
$291.37
Daily Range
$290.37 - $302.96
52-Week Range
$273.11 - $495.55
Estimated Earnings Date
Jul 30, 2026
ALNY News
Best Biotech ETFs to Buy in 2026
ALNY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Alnylam Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
2,500
CEO
Yvonne L. Greenstreet, MD, MBA
Website
www.alnylam.comHeadquarters
Cambridge, MA 02142, US
ALNY Financials
Key Financial Metrics (TTM)
Gross Margin
80.89%
Operating Margin
17.54%
Net Income Margin
13.46%
Return on Equity
98.29%
Return on Capital
24.26%
Return on Assets
11.25%
Earnings Yield
1.44%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$39.14B
Shares Outstanding
133.51M
Volume
1.49M
Avg. Volume
1.12M
Financials (TTM)
Gross Profit
$3.47B
Operating Income
$752.14M
EBITDA
$924.47M
Operating Cash Flow
$712.90M
Capital Expenditure
-$71.56M
Free Cash Flow
$641.34M
Cash & ST Invst.
$3.01B
Total Debt
$1.27B
Alnylam Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.17B
+96.4%
Gross Profit
$956.05M
+82.8%
Gross Margin
81.91%
N/A
Market Cap
$39.14B
N/A
Market Cap/Employee
$17.55M
N/A
Employees
2,230
N/A
Net Income
$205.99M
+458.4%
EBITDA
$304.49M
+2558.2%
Quarterly Fundamentals
Total Cash
$3.01B
+14.3%
Total Debt
$1.27B
-53.2%
Accounts Receivable
$883.96M
+111.5%
Inventory
$84.03M
+28.1%
Long Term Debt
$1.23B
-52.7%
Short Term Debt
$45.66M
-64.3%
Return on Assets
11.25%
N/A
Return on Invested Capital
19.90%
N/A
Free Cash Flow
$48.67M
+138.2%
Operating Cash Flow
$70.50M
+159.6%